SCHEMBL2481068

SCHEMBL2481068

CCN(O)C(=O)c1c[c]ccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.38
HPGD P15428 5/20 0.38
TDP1 Q9NUW8 1/20 0.37
MAPT P10636 1/20 0.34
PGR P06401 1/20 0.34
ADRA2A P08913 1/20 0.34
ADRA2B P18089 1/20 0.34
HTR2A P28223 1/20 0.34
HRH1 P35367 1/20 0.34
KCNH2 Q12809 1/20 0.34
HTT P42858 1/20 0.32
CES2 O00748 2/20 0.32
CES1 P23141 2/20 0.32
HDAC1 Q13547 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
TSHR P16473 2/20 0.31
GLA P06280 1/20 0.31
LMNA P02545 1/20 0.31
NPC1 O15118 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1206309 0.84 HPGD (0.54) ALDH1A1HPGDTDP1MAPTHTT
SCHEMBL2901107 0.83 HPGD (0.40) ALDH1A1HPGDTDP1MAPTPGR
SCHEMBL3341818 0.80 ALDH1A1 (0.36) ALDH1A1HPGDTDP1MAPTPGR
SCHEMBL3022483 0.79 NAMPT (0.42) ALDH1A1HPGDTDP1MAPTPGR
SCHEMBL2225457 0.78 HPGD (0.38) ALDH1A1HPGDTDP1MAPTL3MBTL1
SCHEMBL391457 0.78 ALDH1A1 (0.42) ALDH1A1HPGDTDP1MAPTCES2
SCHEMBL15475072 0.78 TP53 (0.51) ALDH1A1HPGDTDP1HTR2AHDAC1
SCHEMBL16794763 0.77 ALDH1A1 (0.58) ALDH1A1HPGDMAPTPGRADRA2A
SCHEMBL27848441 0.75 CES2 (0.35) ALDH1A1HPGDTDP1CES2CES1
SCHEMBL9123942 0.75 HPGD (0.48) ALDH1A1HPGDMAPTL3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3123864-A1 IMIDAZOPYRAZINE SYK INHIBITORS Gilead Connecticut, Inc. (US) 2017-02-01 EP claimed
US-20130267496-A1 IMIDAZOPYRAZINE SYK INHIBITORS GILEAD CONNECTICUT, INC. (US) 2013-10-10 US claimed
US-20130237520-A1 IMIDAZOPYRAZINE SYK INHIBITORS GILEAD CONNECTICUT, INC. (US) 2013-09-12 US claimed
EP-2373169-A1 IMIDAZOPYRAZINE SYK INHIBITORS Gilead Connecticut, Inc. (US) 2011-10-12 EP claimed
US-20100222323-A1 IMIDAZOPYRAZINE SYK INHIBITORS Kronos Bio, Inc. 2010-09-02 US claimed
WO-2010068257-A1 IMIDAZOPYRAZINE SYK INHIBITORS CGI PHARMACEUTICALS, INC. (US) 2010-06-17 WO claimed
US-20180086769-A1 IMIDAZOPYRAZINE SYK INHIBITORS Kronos Bio, Inc. 2018-03-29 US disclosed
US-9796718-B2 6-(benzo[d]thiazol-5-yl)-n-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine GILEAD CONNECTICUT, INC. (US) 2017-10-24 US disclosed
EP-3123864-A1 IMIDAZOPYRAZINE SYK INHIBITORS Gilead Connecticut, Inc. (US) 2017-02-01 EP disclosed
EP-2716157-B1 Imidazopyrazine Syk inhibitors GILEAD CONNECTICUT INC (US) 2016-05-18 EP disclosed
US-20160031894-A1 IMIDAZOPYRAZINE SYK INHIBITORS Kronos Bio, Inc. 2016-02-04 US disclosed
US-9212191-B2 6-(2,3-dihydro-1H-pyrido-[2,3-b][1,4]oxazin-7-yl)-N-(4-morpholinophenyl)imidazo[1,2-a] pyrazin-8-amine as a spleen tyrosine kinase inhibitor GILEAD CONNECTICUT, INC. (US) 2015-12-15 US disclosed
US-9120811-B2 6-(1H-indazol-6-YL)-N-(4-morpholinophenyl)imidazo[1,4-A]pyrazin-8-amine for treating leukemia or lymphoma GILEAD CONNECTICUT, INC. (US) 2015-09-01 US disclosed
US-20130237520-A1 IMIDAZOPYRAZINE SYK INHIBITORS GILEAD CONNECTICUT, INC. (US) 2013-09-12 US disclosed
US-8455493-B2 Imidazopyrazine Syk inhibitors GILEAD CONNECTICUT, INC. (US) 2013-06-04 US disclosed
US-8450321-B2 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor GILEAD CONNECTICUT, INC. (US) 2013-05-28 US disclosed
US-20120220582-A1 IMIDAZOPYRAZINE SYK INHIBITORS GILEAD CONNECTICUT, INC. (US) 2012-08-30 US disclosed
EP-2373169-A1 IMIDAZOPYRAZINE SYK INHIBITORS Gilead Connecticut, Inc. (US) 2011-10-12 EP disclosed
US-20100222323-A1 IMIDAZOPYRAZINE SYK INHIBITORS Kronos Bio, Inc. 2010-09-02 US disclosed
WO-2010068257-A1 IMIDAZOPYRAZINE SYK INHIBITORS CGI PHARMACEUTICALS, INC. (US) 2010-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160031894-A1 IMIDAZOPYRAZINE SYK INHIBITORS SYK, BTK, ZAP70 ALDH1A1 4166/4885HPGD 2647/4885TDP1 626/4885
US-20120220582-A1 IMIDAZOPYRAZINE SYK INHIBITORS SYK, BTK, ZAP70 ALDH1A1 4166/4885HPGD 2647/4885TDP1 626/4885
US-20130237520-A1 IMIDAZOPYRAZINE SYK INHIBITORS SYK, BTK, ZAP70 ALDH1A1 4166/4885HPGD 2647/4885TDP1 626/4885
US-20180086769-A1 IMIDAZOPYRAZINE SYK INHIBITORS SYK, BTK, ZAP70 ALDH1A1 4166/4885HPGD 2647/4885TDP1 626/4885
US-20130267496-A1 IMIDAZOPYRAZINE SYK INHIBITORS SYK, BTK, ZAP70 ALDH1A1 4166/4885HPGD 2647/4885TDP1 626/4885
US-20100222323-A1 IMIDAZOPYRAZINE SYK INHIBITORS SYK, BTK, ZAP70 ALDH1A1 4166/4885HPGD 2647/4885TDP1 626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.